Dennis Panelo

James Molloy

- Quoin Pharmaceuticals announced a private placement financing with the potential to raise up to **$104.5 million** in gross proceeds.  **[1671502_0001104659-25-099735_tm2528687d1_ex99-1.htm:0]** 
- The financing includes **$16.5 million** in initial upfront funding and up to an additional **$88.0 million** upon the potential cash exercise of accompanying warrants.  **[1671502_0001104659-25-099735_tm2528687d1_ex99-1.htm:0]** 
- The company will issue **1,993,940 American Depository Shares (ADSs)** (or pre-funded warrants) and accompanying warrants to purchase up to **7,975,760 ADSs** at a combined purchase price of **$8.25 per ADS** and accompanying warrants.  **[1671502_0001104659-25-099735_tm2528687d1_ex99-1.htm:1]** 
- The proceeds are intended for general corporate purposes, including operating expenses, research and development for QRX003 for Netherton Syndrome, working capital, and future acquisitions.  **[1671502_0001104659-25-099735_tm2528687d1_ex99-1.htm:1]** 
- The aggregate net proceeds, assuming full warrant exercise, are expected to fund the company into **2027**.  **[1671502_0001104659-25-099735_tm2528687d1_ex99-1.htm:1]** **[1671502_0001104659-25-099735_tm2528687d1_8k.htm:2]**

Quoin Pharmaceuticals (QNRX)